Archive
Proactive news snapshot: Verona Pharma, Anglo African Oil & Gas, Faron Pharmaceuticals, KRM22 …
A glance at some of the day's highlights from the Proactive Investors newswire
Company
Verona Pharma
LON:VRP
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.
58 stories · page 2 of 3
Verona Pharma shares jump after COPD study delivers "impressive" results
Gary Ferguson, who led the four-week study of 416 people with chronic obstructive pulmonary disease, said: “The strong effect on both bronchodilation and quality of life as an add-on to tiotropium is impressive and consistent with prior stu
Verona Pharma appoints investor relations specialist to develop company's profile
David Moskowitz, who held similar positions at Trovagene and Biocept, has been appointed to the newly created role
Verona Pharma chief excited by COPD drug's potential
“We believe ensifentrine, with its unique dual mode of action and bronchodilator and anti-inflammatory properties, has the potential to become an important additional treatment option for many of these patients,” said CEO Jan-Anders Karlsso
Verona Pharma expects data from clinical trial around the end of the year
The phase IIb study will assess the safety and efficacy of its inhaled treatment for obstructive pulmonary disease
Verona Pharma to use industry conference to expand on lung disease treatment data
Chief medical officer Kathleen Rickard will present the new information on nebulised ensifentrine at the CHEST Annual Meeting in New Orleans
Verona Pharma PLC excited about the progress of ensifentrine through clinical trials
Recent trial results support the view that the drug could be an effective bronchodilator in COPD patients via various delivery methods
Verona Pharma: The AIM-quoted drug developer built on the research of a Glaxo legend
Sir David Jack's team were responsible for the discovery of several huge drugs, and RPL554, a compound he helped develop later on in his career, is now being taken through the clinic by Verona
Investments and investor services
FTSE 100 closes firmly in red as traders fret about trade
Stock markets in Europe have suffered severe declines as US-China trade tensions have heightened
Verona Pharma pushing ahead with development of lead drug despite recent splutter
Verona’s COPD treatment, ensifentrine, failed to meet the primary endpoint in a Phase 2 trial last month, but the results were encouraging enough for the company to keep the faith
Verona Pharma splutters as lead COPD drug disappoints in Phase II study
Ensifentrine was shown to be more effective than a placebo, although it didn’t improve patients’ breathing by as much as hoped
Archive
US midterm elections, Primark, Morrisons and Imperial Brands make for busy day ahead
The day ahead will see Americans go to the polls to vote in the midterm elections but closer to home the focus is on financials from AB Foods, Morrison's and Imperial Brands
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target
Arix Biosciences making progress as well as adding value
Three of Arix's investee companies will be busy in the coming months, while a fourth now has the financial runway to expand its ground-breaking research
Archive
Other financials to take up the results mantle, with Standard Life Aberdeen and Hargreaves Lansdown due on Tuesday
Aside from the two financial blue chips, updates are also due on Tuesday from FTSE 100-listed InterContinental Hotels, and FTSE 250-listed Domino's Pizza
Arix Biosciences' progress significantly undervalued, suggests US broker
Arix’s portfolio companies are involved in 15 clinical trials
Verona Pharma's chief medical officer to quit at the end of the month
The search is already underway for Kenneth Newman's replacement
Milestone Group jumps as digital media company enters blockchain joint venture agreement
A look at some of the biggest risers and fallers in London on Monday